Merck & Co., Inc. Increase (Decrease) in Restricted Cash and Investments
Merck & Co., Inc. (MRK) reported Increase (Decrease) in Restricted Cash and Investments of -$34.00 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments · last filed 2013-02-28
- Merck & Co., Inc. increase (decrease) in restricted cash and investments for fiscal 2012 was -$34.00M.
- Merck & Co., Inc. increase (decrease) in restricted cash and investments for fiscal 2010 was -$276.00M.
- Merck & Co., Inc. increase (decrease) in restricted cash and investments for fiscal 2009 was -$5.55B.
| Period end | Increase (Decrease) in Restricted Cash and Investments 12 month |
|---|---|
| 2012-12-31 | -$34.00M 10-K · filed 2013-02-28 |
| 2010-12-31 | -$276.00M 10-K · filed 2013-02-28 |
| 2009-12-31 | -$5.55B 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |